Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) FCF Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1,388.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3,383.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -89.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1,183.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 26,102.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 769.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 984.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -902,489.00 |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 2,263.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,263.00 |
| Mar 31, 2026 | -2,089.00 |
| Dec 31, 2025 | 4.11 Mn |
| Sep 30, 2025 | 1,828.00 |
| Jun 30, 2025 | 2,657.00 |
| Mar 31, 2025 | 3,912.00 |
| Dec 31, 2024 | 566.00 |
| Sep 30, 2024 | 3,107.00 |
| Jun 30, 2024 | 2,198.00 |
| Mar 31, 2024 | 1,119.00 |
| Dec 31, 2023 | 2,050.00 |
| Sep 30, 2023 | 1,894.00 |
| Jun 30, 2023 | 1,936.00 |
| Mar 31, 2023 | 8,734.00 |
| Dec 31, 2022 | 4,054.00 |
| Sep 30, 2022 | 1,465.00 |
| Jun 30, 2022 | 976.00 |
| Mar 31, 2022 | 16,398.00 |
| Dec 31, 2021 | 99,172.00 |
| Sep 30, 2021 | 57,207.00 |